MarketCap
Facebook
X
TelegramAdamas Pharmaceuticals, Inc. Total Assets 2011-2026 | ADMS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Adamas Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 120 M | 162 M | 235 M | 186 M | 142 M | 129 M | 161 M | 86.2 M | 64.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 235 M | 64.3 M | 143 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
62.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
1.3 B | $ 220.94 | 2.51 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
MediWound Ltd.
MDWD
|
31.1 M | $ 17.08 | 2.83 % | $ 465 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 19.7 | 2.44 % | $ 921 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Mesoblast Limited
MESO
|
662 M | $ 15.54 | 8.48 % | $ 10.1 B |  Australia |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Mirum Pharmaceuticals
MIRM
|
843 M | $ 90.9 | 3.44 % | $ 4.56 B | USA |
 |
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Cara Therapeutics
CARA
|
126 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
MediciNova
MNOV
|
45.6 M | $ 1.44 | -0.68 % | $ 70.7 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.36 | 3.03 % | $ 347 M | Britain |
 |
CytomX Therapeutics
CTMX
|
152 M | $ 4.41 | 3.98 % | $ 608 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
4.09 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
426 M | - | - | $ 3.74 B | USA |
 |
Merck & Co.
MRK
|
137 B | $ 118.9 | 2.17 % | $ 297 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
986 M | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
8.23 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Bellerophon Therapeutics
BLPH
|
7.94 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Neurocrine Biosciences
NBIX
|
4.63 B | $ 131.82 | 3.1 % | $ 13.1 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
94.6 M | $ 4.56 | 5.68 % | $ 874 M | Canada |
 |
Homology Medicines
FIXX
|
61.8 M | - | 0.77 % | $ 53.4 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |